- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Breast MR spectroscopy reduces false positives
Spectroscopy can help reduce breast MRI false positives, which tend to increase at various stages of the menstrual cycle, according to researchers at Memorial Sloan-Kettering Cancer Center.
Spectroscopy can help reduce breast MRI false positives, which tend to increase at various stages of the menstrual cycle, according to researchers at Memorial Sloan-Kettering Cancer Center.
Researchers led by Dr. Lia Bartella performed prospective MRS scans on 27 high-risk subjects undergoing screening breast MRI. Eight were in different stages of their menstrual cycle. The investigators defined a positive MRS as having a choline peak greater than or equal to 2.
The protocol was tested in healthy breast tissue contralateral to the diseased breast. Researchers found that choline did not vary in any of the women and ruled out false positives regardless of a subject's menstrual cycle stage. The result is confidence in true-positive and true-negative findings when they perform MRS in the breast, Bartella said at the 2005 RSNA meeting.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
